Q3 2024 · 13F-HR
Novo Holdings A/Sholdings as filed
Filed 2024-10-24 · accession 0000950123-24-009887
$2.01B
Reported value
37
Positions
2024-09-30
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 922908769 | VTI | VANGUARD INDEX FDS | $294.1M | 14.6% | 1,038,550 | Common | SOLE |
| 88023B103 | TEM | TEMPUS AI INC | $230.6M | 11.5% | 4,074,419 | Common | SOLE |
| 11271J107 | BN | BROOKFIELD CORP | $185.6M | 9.22% | 3,491,230 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $148.1M | 7.36% | 5,549,900 | Common | SOLE |
| 218352102 | CORT | CORCEPT THERAPEUTICS INC | $111.6M | 5.54% | 2,411,362 | Common | SOLE |
| N07059210 | ASML | ASML HOLDING N V | $111.1M | 5.52% | 133,336 | Common | SOLE |
| 79466L302 | CRM | SALESFORCE INC | $100.9M | 5.01% | 368,560 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $85.7M | 4.26% | 750,000 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS INC | $58.5M | 2.91% | 1,500,000 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $54.3M | 2.69% | 2,385,000 | Common | SOLE |
| 01609W102 | BABA | ALIBABA GROUP HLDG LTD | $53.1M | 2.64% | 500,827 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $52.9M | 2.63% | 724,666 | Common | SOLE |
| 22663K107 | CRNX | CRINETICS PHARMACEUTICALS IN | $51.1M | 2.54% | 1,000,000 | Common | SOLE |
| 12685J105 | CABO | CABLE ONE INC | $41.4M | 2.06% | 118,403 | Common | SOLE |
| 04272N102 | AVBP | ARRIVENT BIOPHARMA INC | $35.4M | 1.76% | 1,505,315 | Common | SOLE |
| N5749R100 | 2GH | MERUS N V | $35.0M | 1.74% | 700,000 | Common | SOLE |
| 09061G101 | BMRN | BIOMARIN PHARMACEUTICAL INC | $34.4M | 1.71% | 490,000 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $32.8M | 1.63% | 963,663 | Common | SOLE |
| 02043Q107 | ALNY | ALNYLAM PHARMACEUTICALS INC | $32.6M | 1.62% | 118,383 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $31.9M | 1.59% | 1,725,000 | Common | SOLE |
| 51655R101 | — | LANZATECH GLOBAL INC | $30.2M | 1.50% | 15,814,845 | Common | SOLE |
| 113004105 | BAM | BROOKFIELD ASSET MANAGMT LTD | $29.7M | 1.47% | 627,207 | Common | SOLE |
| 14179K101 | CRGX | CARGO THERAPEUTICS INC | $28.5M | 1.41% | 1,544,000 | Common | SOLE |
| 03152W109 | AM6 | AMICUS THERAPEUTICS INC | $26.7M | 1.33% | 2,500,000 | Common | SOLE |
| 77313F106 | RCKT | ROCKET PHARMACEUTICALS INC | $20.3M | 1.01% | 1,100,000 | Common | SOLE |
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $19.5M | 0.97% | 1,150,000 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $16.2M | 0.81% | 1,500,000 | Common | SOLE |
| 09627Y109 | 2655787D | BLUEPRINT MEDICINES CORP | $16.2M | 0.80% | 175,000 | Common | SOLE |
| 92539P101 | — | VERVE THERAPEUTICS INC | $11.6M | 0.58% | 2,400,000 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $10.1M | 0.50% | 1,122,581 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $9.0M | 0.45% | 1,850,000 | Common | SOLE |
| 59102M104 | MGX | METAGENOMI INC | $3.9M | 0.19% | 1,800,000 | Common | SOLE |
| 449778109 | IOBTQ | IO BIOTECH INC | $3.5M | 0.17% | 3,354,449 | Common | SOLE |
| 00288U106 | ABCL | ABCELLERA BIOLOGICS INC | $2.9M | 0.15% | 1,126,915 | Common | SOLE |
| 57142B104 | MQ | MARQETA INC | $2.2M | 0.11% | 441,558 | Common | SOLE |
| 36322Q206 | DMRA | GALECTO INC | $1.2M | 0.06% | 99,913 | Common | SOLE |
| 84833T103 | SPRO | SPERO THERAPEUTICS INC | $628,329 | 0.03% | 468,902 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.